Verve Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid in USD from Q3 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease.
Summary
Verve Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid history and growth rate from Q3 2021 to Q1 2025.
  • Verve Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid for the quarter ending March 31, 2025 was $92.7M, a 10.3% decline year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, YoY Quarterly Growth (%)

Verve Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid (USD)

Period Value YoY Chg Change % Date Report Filed
Q1 2025 $92.7M -$10.7M -10.3% Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $95.4M -$10.6M -10% Dec 31, 2024 10-K 2025-02-27
Q3 2024 $98.1M -$11.4M -10.4% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $101M -$11.3M -10.1% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $103M -$12.4M -10.7% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $106M -$13.1M -11% Dec 31, 2023 10-K 2024-02-27
Q3 2023 $109M -$9.54M -8.02% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $112M +$3.91M +3.62% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $116M +$6.87M +6.3% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $119M +$10.4M +9.55% Dec 31, 2022 10-K 2023-03-02
Q3 2022 $119M +$10.2M +9.36% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $108M Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $109M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $109M Dec 31, 2021 10-K 2022-03-14
Q3 2021 $109M Sep 30, 2021 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.